Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.81 |
| ▸ | CA5A | P35218 | 2/20 | 0.57 |
| ▸ | PKM | P14618 | 2/20 | 0.57 |
| ▸ | CA12 | O43570 | 1/20 | 0.57 |
| ▸ | CA1 | P00915 | 1/20 | 0.57 |
| ▸ | CA2 | P00918 | 1/20 | 0.57 |
| ▸ | CA3 | P07451 | 1/20 | 0.57 |
| ▸ | CA4 | P22748 | 1/20 | 0.57 |
| ▸ | CA6 | P23280 | 1/20 | 0.57 |
| ▸ | CA7 | P43166 | 1/20 | 0.57 |
| ▸ | CA9 | Q16790 | 1/20 | 0.57 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.57 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.57 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.53 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.44 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29530815 | 1.00 | LMNA (0.81) | LMNACA5APKMCA12CA1 | |
| SCHEMBL19272079 | 0.91 | LMNA (0.68) | LMNACA5APKMCA12CA1 | |
| Acetosyringone SCHEMBL15511 | 0.90 | LMNA (1.00) | LMNACA5APKMCA12CA1 | |
| SCHEMBL4545186 | 0.87 | LMNA (0.62) | LMNACA5APKMCA12CA1 | |
| SCHEMBL14516907 | 0.87 | LMNA (0.62) | LMNACA5APKMCA12CA1 | |
| SCHEMBL2338863 | 0.86 | LMNA (0.84) | LMNACA5APKMCA12CA1 | |
| SCHEMBL29393519 | 0.84 | CA12 (0.81) | LMNACA5APKMCA12CA1 | |
| SCHEMBL17655678 | 0.84 | CA12 (0.81) | LMNACA5APKMCA12CA1 | |
| SCHEMBL6944075 | 0.82 | LMNA (0.78) | LMNACA5APKMCA12CA1 | |
| SCHEMBL12396894 | 0.82 | LMNA (0.78) | LMNACA5APKMCA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020187155-A1 | USE OF APOCYNIN DIMER ANALOGUE DERIVATIVE IN PREPARING MEDICAMENT OR HEALTH CARE PRODUCT FOR PREVENTING AND TREATING PARKINSON'S DISEASE | 暨南大学 | 2020-09-24 | — | — | WO | disclosed |
| US-20190032098-A1 | PROCESS FOR PREPARING BIPHENYL COMPOUNDS | UNIV BORDEAUX (FR) | 2019-01-31 | — | — | US | disclosed |
| US-20170240937-A1 | NEW PROCESS FOR PREPARING BIPHENYL COMPOUNDS | UNIVERSITÉ DE BORDEAUX (FR) | 2017-08-24 | — | — | US | disclosed |
| US-20170240937-A1 | NEW PROCESS FOR PREPARING BIPHENYL COMPOUNDS | UNIVERSITÉ DE BORDEAUX (FR) | 2017-08-24 | — | — | US | disclosed |
| EP-2424872-B1 | NEUROPROTECTIVE COMPOUNDS AND THEIR USE | MEDICAL COLLEGE OF WISCONSIN INC (US) | 2017-05-17 | — | — | EP | disclosed |
| WO-2016050988-A1 | NEW PROCESS FOR PREPARING BIPHENYL COMPOUNDS | UNIVERSITÉ DE BORDEAUX (FR) | 2016-04-07 | — | — | WO | disclosed |
| EP-3002333-A1 | Process for preparing biphenyl compounds | Université de Bordeaux (FR) | 2016-04-06 | — | — | EP | disclosed |
| US-8962600-B2 | Neuroprotective compounds and their use | THE MEDICAL COLLEGE OF WISCONSIN, INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-20120108549-A1 | NEUROPROTECTIVE COMPOUNDS AND THEIR USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-05-03 | — | — | US | disclosed |
| WO-2010126719-A1 | NEUROPROTECTIVE COMPOUNDS AND THEIR USE | MCW RESEARCH FOUNDATION, INC. (US) | 2010-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190032098-A1 | PROCESS FOR PREPARING BIPHENYL COMPOUNDS | CYP1B1, CYP1A1, CYP1A2 | LMNA 1727/4885CA5A 395/4885PKM 1548/4885 |
| US-20170240937-A1 | NEW PROCESS FOR PREPARING BIPHENYL COMPOUNDS | CYP1B1, CYP1A1, CYP1A2 | LMNA 2345/4885CA5A 204/4885PKM 1892/4885 |
| US-20120108549-A1 | NEUROPROTECTIVE COMPOUNDS AND THEIR USE | NLN, ATP6V1B2, BDNF | LMNA 653/4885CA5A 2550/4885PKM 2960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.